SEARCH WITHIN CONTENT
VOLUME 11 , ISSUE 1 ( October, 2014 ) > List of Articles
V. Sai Vishnupriyaa, G. Mohanapriya, S. Dhalapathy, S. Zahir Hussain, M.N. Kamaludeen
Citation Information : Sai Vishnupriyaa V, Mohanapriya G, Dhalapathy S, Zahir Hussain S, Kamaludeen M. Management of Insulinoma – Our Institutional (MMC) Experience. 2014; 11 (1):14-18.
License: CC BY-NC 4.0
Published Online: 10-02-2021
Copyright Statement: Copyright © 2014; Jaypee Brothers Medical Publishers (P) Ltd.
Introduction Hyperinsulinemia is a clinical syndrome with diverse etiology. Though Insulinoma is rare it is the most common functioning pancreatic islet cell tumour with annual incidence of 0.5-1 per million of the population. Insulinoma is four times more common in females1. They are usually sporadic but may occur as a part of MEN 1 (16%). They occur at any age but present most commonly in middle age. Median age of diagnosis is 47 years for sporadic cases and 23 years for cases associated with MEN I. Most Insulinomas are solitary (90%), small <1cm (65%), intrapancreatic (99%) and or benign (90%). 16% are associated with MEN 1 and are often multiple, malignant in 25% of cases and have high recurrence rate2.
© Jaypee Brothers Medical Publishers (P) LTD.